EVUSHELD  significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

21.04.2022 - Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary ...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Colorado ,United States ,France ,Spain ,Belgium ,Great Britain ,Myronj Levin , ,Vanderbilt University Medical Center ,Department Of Defense ,Astrazeneca ,Department Of Health ,University Of Colorado School Medicine ,European Union ,Nuclear Defense ,Centers For Disease ,European Congress ,Biomedical Advanced Research ,Human Services ,World Health Organization ,Program Executive Office For Chemical ,Development Authority ,Washington University School Of Medicine ,Regulatory Agency ,Office Of The ,New England Journal ,Colorado School ,Executive Vice President ,Clinical Microbiology ,Infectious Diseases ,Cosmetic Act ,Emergency Use Authorization ,Specific Populations ,Full Fact Sheet ,Healthcare Providers ,Fact Sheet ,Parents And ,Washington University School ,Assistant Secretary ,Joint Program Executive Office ,Rare Diseases ,Immunosuppression Among ,Zeneca Data ,Disease Control ,Immunocompetence Guidelines ,Single Dose ,Solid Organ Transplant ,Extended Half Life ,Antimicrobial Agents ,Healthy Preterm ,Pediatr Infect Dis ,